Trial Profile

A Phase 2, Open-Label, Single-Arm Study of Single-Dose Lead-In and Neoadjuvant Trilaciclib and Chemotherapy in Patients With Early-Stage Triple Negative Breast Cancer (TNBC)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trilaciclib (Primary) ; Anthracyclines; Carboplatin; Cyclophosphamide; Doxorubicin; Paclitaxel; Pembrolizumab; Taxanes
Indications Carcinoma; Early breast cancer; Triple negative breast cancer
Focus Pharmacodynamics
Sponsors G1 Therapeutics

Most Recent Events

08 Jan 2024 Results published in the G1 Therapeutics Media Release.
06 Jun 2023 Results combining immune analysis with clinical outcomes to identify correlates of treatment response, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
04 Jun 2023 According to a G1 Therapeutics media release, data from this study presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com